AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Career Advice

Top Life Science Companies Hiring Now in July

According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!

July 1, 2019

1 min read

BioSpace Staff

Deals

AbbVie’s Latest Acquisition Offers Solution for ‘Life After Humira’

Humira generates about 60% of AbbVie’s annual revenue but is expected to lose patent protection in 2023.

June 26, 2019

3 min read

Alex Keown

Deals

AbbVie Makes ‘Transformational’ Move with $63 Billion Acquisition of Allergan

The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.

June 25, 2019

3 min read

Alex Keown

Drug Development

AbbVie Resumes Multiple Myeloma Trial After FDA Lifts Partial Hold

The partial clinical hold was lifted after the company revised the study protocol for the trial. The partial clinical hold remains on other multiple myeloma trials involving venetoclax.

June 24, 2019

3 min read

Alex Keown

BioMidwest

AbbVie Employees to Help Underserved Communities in Sixth-Annual “Week of Possibilities”

Approximately 9,000 employees participate in volunteer activities to update schools and community centers all over the world benefitting more than 70,000 students and 50,000 community members

June 10, 2019

4 min read

BioForest

Top Life Science Companies Hiring Now in June

According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to look for a job with more challenges and rewarding opportunities?

June 3, 2019

1 min read

BioSpace Staff

Zeposia recieved top line results in the ulcerativ

BioMidwest

Takeda’s Entyvio Superior to Humira in Ulcerative Colitis

The new exploratory data indicated that a larger proportion of patients receiving Entyvio had a clinical response at week 14 compared to those receiving Humira.

May 20, 2019

2 min read

Mark Terry

Drug Development

AbbVie Halts Brain Tumor Study Due to Lack of Survival Benefits

An Independent Data Monitoring Committee recommended the trial be stopped because of lack of survival benefit for patients receiving the drug compared to placebo.

May 17, 2019

2 min read

Mark Terry

Policy

Boehringer Ingelheim and AbbVie Resolve Humira Biosimilar Patent Litigation

Under the terms of the deal, AbbVie will grant Germany-based Boehringer Ingelheim a non-exclusive license for Cyltezo, its biosimilar to Humira.

May 14, 2019

2 min read

Alex Keown

JOBS